Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients
Launched by STEFAN LAKÄMPER · Mar 27, 2025
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how "drug holidays" — short breaks from ADHD medication — affect driving performance in adults with ADHD. ADHD can make it harder to pay attention, which increases the risk of car accidents. While medications can help manage these symptoms, some adults with ADHD choose to take breaks from their medication to feel more like themselves. This study aims to understand how these breaks influence driving abilities using a driving simulator.
To participate in the trial, you need to be an adult diagnosed with ADHD and currently taking stimulant medications. You should also have a history of taking drug holidays on your own and be able to wear contact lenses for vision tracking during the study. Participants will take part in driving simulations while on and off their medication, helping researchers fill an important gap in understanding how these breaks might impact driving safety. The study is not yet recruiting, so there’s time to consider if this is something you or a loved one might be interested in.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • adult drivers
- • ADHD-diagnosed, established ADHD-treatment only with stimulants
- • known history of drug holidays based on own decision,
- • at impaired eyesight with more than +/- 5 diopter or astigmatism
- • contact lenses are required (for eye tracking)
- Exclusion criteria:
- • sensibility to motion sickness (kinetosis, dizziness etc. in 5 min screening drive)
- • non-stimulant-treatment
- • inability to understand the study procedure for linguistic or cognitive reasons
- • professional drivers (if working during the study period)
- • for women: pregnancy
About Stefan Lakämper
Stefan Lakämper is a dedicated clinical trial sponsor renowned for advancing innovative research in the biomedical field. With a focus on enhancing patient outcomes, Lakämper oversees a diverse portfolio of clinical studies, emphasizing rigorous scientific methodology and ethical standards. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, he aims to drive the development of groundbreaking therapies and medical interventions. Committed to transparency and excellence, Lakämper prioritizes the safety and well-being of participants throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, Zrh, Switzerland
Patients applied
Trial Officials
Stefan Lakämper, Dr. rer. nat.
Principal Investigator
University of Zurich
Kristina Keller, Dr. med.
Principal Investigator
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported